The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
MetaVia Inc. filed Post-Effective Amendment No. 2 to its Form S-1 to update the shelf registration to include information from its 2025 Form 10-K and other updates; the prospectus registers up to 936,846 shares for resale by selling securityholders.
The amendment states no additional securities are being registered, that the Company will not receive proceeds from resale by the selling securityholders, and that it would receive up to $30.6 million only if the related warrants are exercised for cash. Shares outstanding were 5,090,936 as of March 20, 2026.
MetaVia Inc. filed a current report to let investors know it has posted an updated corporate presentation dated March 2026 on its investor relations website. The same presentation is attached as Exhibit 99.1 and may be used in future presentations, investor communications, or conferences.
The information in this report, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed for liability purposes under securities laws, unless specifically incorporated by reference elsewhere. The presentation contains forward-looking statements that are subject to important limitations and risk factors described in the company’s SEC reports.
MetaVia Inc. is a clinical-stage biotechnology company developing drugs for cardiometabolic diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), obesity and type 2 diabetes.
The company’s lead asset, vanoglipel (DA-1241), is an oral GPR119 agonist in a 16-week Phase 2a MASH trial. MetaVia reported positive topline results in December 2024, including improvements in liver enzyme ALT versus placebo and favorable signals across liver fat, fibrosis scores and inflammatory biomarkers, with good overall tolerability.
Its second key asset, DA-1726, is a once-weekly injectable oxyntomodulin analog acting as a GLP-1 and glucagon receptor dual agonist for obesity. A Phase 1 trial in obese, otherwise healthy subjects has shown dose-dependent weight loss, reduced waist circumference, improved glucose control and liver stiffness reductions, alongside mainly mild gastrointestinal adverse events.
MetaVia plans additional Phase 1 titration cohorts for DA-1726 through 2026 and is concentrating resources on these two Dong-A ST–licensed programs, while seeking out-licensing or divestiture opportunities for four legacy assets in viral, neurodegenerative and lipid disorders.
MetaVia Inc. reported full-year 2025 results and a cardiometabolic pipeline update. Cash and cash equivalents were $10.3 million at year-end, and a January 2026 public offering raised $9.3 million, which together are expected to fund operations into the fourth quarter of 2026.
For 2025, MetaVia posted a net loss of $12.97 million, improving from a $27.59 million loss in 2024, as research and development expenses fell to $6.80 million from $21.55 million. Loss per share narrowed to $(7.35) from $(39.13), with 1.77 million weighted-average shares outstanding.
Lead obesity candidate DA-1726 showed 9.1% weight loss with improved glucose control and liver measures in a Phase 1 48 mg cohort, and is backed by 39 granted and pending patents with protection at least through 2041. A 16-week titration Phase 1 Part 3 study at 48 mg and 64 mg has IRB approval, with dosing expected to begin in April 2026 and data anticipated in the fourth quarter of 2026.
MetaVia Inc. filed an 8-K to report that an Institutional Review Board at Clinical Pharmacology of Miami has approved Phase 1 Part 3 of its obesity trial for lead drug DA-1726, a dual GLP-1 and glucagon receptor agonist. The 16-week study will enroll 40 obese but otherwise healthy adults in two cohorts, testing one-step titration up to 48 mg and two-step titration up to 64 mg. It will track safety, side effects, pharmacokinetics, and multiple metabolic and body composition measures. MetaVia plans to begin dosing in April 2026 and expects data in the fourth quarter of 2026, building on earlier Phase 1 results where the 48 mg dose produced about 9% weight loss and improved glucose and waist measures.
MetaVia Inc. Chief Financial Officer Woodworth Marshall H received a grant of 28,000 shares of common stock on January 23, 2026, reported as an acquisition at a price of $0 per share. This represents restricted stock units issued under the company’s 2022 Amended and Restated Equity Incentive Plan.
The grant vests in two equal parts, with 50% vesting on each of the first and second anniversaries of the grant date, contingent on continued service. Following this award, the officer beneficially owns 30,734 shares directly, a figure that reflects MetaVia’s completed 1-for-11 reverse stock split on December 4, 2025.
MetaVia Inc. filed an 8-K to disclose final 2025 cash bonuses for its top executives and to update its “Summary Compensation Table for 2025 and 2024.” The Compensation Committee approved discretionary cash bonuses for the company’s principal executive officer and other named executive officers for the fiscal year ended December 31, 2025.
For 2025, President and Chief Executive Officer Hyung Heon Kim received salary of $479,723, a bonus of $239,862, and total compensation of $756,328. Chief Financial Officer Marshall H. Woodworth received salary of $393,300, a bonus of $157,320, and total compensation of $562,985. For 2025, “All Other Compensation” for the named executives was related to health and welfare benefits paid by MetaVia.
MetaVia Inc. insider activity: CEO and President Kim Hyung Heon, who also serves as a director of MetaVia Inc. (MTVA), received 32,000 shares of common stock on January 23, 2026 in a transaction coded "A" for acquisition at a price of $0 per share. The filing explains this represents a grant of restricted stock units under MetaVia's 2022 Amended and Restated Equity Incentive Plan, vesting 50% on each of the first and second anniversaries of the grant date, subject to continued service.
After this award, Kim Hyung Heon beneficially owns 37,545 shares of MetaVia common stock directly. The filing notes this ownership figure reflects MetaVia’s completed 1-for-11 reverse stock split on December 4, 2025.
MetaVia Inc. completed an underwritten public offering of Class A and Class B units, raising approximately $7.7 million in net proceeds. The company sold 1,006,870 Class A Units, each with one common share plus Series C and Series D common warrants, and 1,998,704 Class B Units, each with a pre-funded warrant plus additional Series C and Series D warrants. The Series C and Series D warrants are immediately exercisable at $3.10 per share, with the Series C warrants expiring five years after January 16, 2026 and the Series D warrants expiring two years after that date.
MetaVia plans to use the net proceeds for working capital and general corporate purposes, including continuing clinical development of its obesity candidate DA-1726. The underwriter received a 45-day over-allotment option for additional shares and warrants, which was fully exercised, and company executives and directors agreed to a 75-day lock-up on sales of company securities following the offering’s closing.
MetaVia Inc. is offering 614,840 Class A Units and 1,998,704 Class B Units, plus 9,839,336 shares of common stock issuable upon exercise of pre-funded and common warrants. Each Class A Unit includes one common share and 1.5 Series C and 1.5 Series D common warrants at a combined price of $3.10; each Class B Unit replaces the share with a pre-funded warrant at $3.099. Gross proceeds are expected to be about $8.10 million, with estimated net proceeds of approximately $6.6 million before any warrant exercises.
MetaVia plans to use the cash primarily for working capital and to continue developing DA-1726 for obesity. The company is a clinical-stage biotech also advancing Vanoglipel (DA-1241) for MASH and Type 2 diabetes and recently reported positive Phase 1 and Phase 2a topline data. MetaVia reports preliminary year-end 2025 cash of about $10.3 million with no debt and expects current resources plus this offering to fund operations into the third quarter of 2026, but it has a substantial accumulated deficit and a going concern warning.